Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study
The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-contro...
Saved in:
| Published in | Nutrients Vol. 11; no. 11; p. 2580 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
25.10.2019
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (−2.40% (95% CI −3.79, −1.01); p < 0.001), waist circumference (−2.76% (95% CI −4.55, −0.96); p = 0.003), HbA1c (−0.95% (95% CI −1.22, −0.67); p < 0.001), plasma lipids, FLI (−21.83% (95% CI −27.39, −16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (−39.48% (95% CI −47.98, −30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects. |
|---|---|
| AbstractList | The objective was to evaluate the effects of 6 months of supplementation with Altilix
, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix
(26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix
supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (-2.40% (95% CI -3.79, -1.01);
< 0.001), waist circumference (-2.76% (95% CI -4.55, -0.96);
= 0.003), HbA1c (-0.95% (95% CI -1.22, -0.67);
< 0.001), plasma lipids, FLI (-21.83% (95% CI -27.39, -16.27);
< 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12);
< 0.001), and carotid intima-media thickness (-39.48% (95% CI -47.98, -30.97);
< 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix
supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix
supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects. [...]increasing evidence indicates that specific supplements or nutraceuticals have important hepatoprotective roles, improving liver enzymes as well as liver steatosis and its prognosis [18]. [...]a hypothesis of the present study was that the supplementation of a Cynara cardunculus (L.) subsp. scolymus Hayek-based nutraceutical, named Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, can improve different cardio-metabolic markers in patients with metabolic syndrome (MetS) in a 6 month follow-up study. [...]we found in subjects from the Altilix® supplemented vs. placebo groups, regarding MetS comorbidities, a significant improvement in glucose metabolism parameters (including HbA1c, insulin resistance, and pancreatic β-cell function), in agreement with some in vitro and in vivo literature data [34,35,36]. [...]this lipid-lowering effect could be, in turn, attributed to the presence in Altilix® of chlorogenic acid, which is associated with a direct action on the liver, the excretion of biliary salts, and acids rich in cholesterol [34,40]. [...]our findings, proposing a direct effect of artichoke extract on lipids affecting liver-related parameters, particularly TG, result in being, again, of huge clinical value, since the accumulation of TG in hepatocytes is largely involved in NAFLD development and progression [41]. [...]it may be considered that the intake of Cynara cardunculus extract can lead to the removal of dangerous toxins, facilitation of bile production, assisting fat digestion and significantly preventing the lipid peroxidation process in cell membranes of liver tissues, as well as oxidative damage in hepatocyte membranes [44,45]. The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (−2.40% (95% CI −3.79, −1.01); p < 0.001), waist circumference (−2.76% (95% CI −4.55, −0.96); p = 0.003), HbA1c (−0.95% (95% CI −1.22, −0.67); p < 0.001), plasma lipids, FLI (−21.83% (95% CI −27.39, −16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (−39.48% (95% CI −47.98, −30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects. The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (-2.40% (95% CI -3.79, -1.01); p < 0.001), waist circumference (-2.76% (95% CI -4.55, -0.96); p = 0.003), HbA1c (-0.95% (95% CI -1.22, -0.67); p < 0.001), plasma lipids, FLI (-21.83% (95% CI -27.39, -16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (-39.48% (95% CI -47.98, -30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects.The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (-2.40% (95% CI -3.79, -1.01); p < 0.001), waist circumference (-2.76% (95% CI -4.55, -0.96); p = 0.003), HbA1c (-0.95% (95% CI -1.22, -0.67); p < 0.001), plasma lipids, FLI (-21.83% (95% CI -27.39, -16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (-39.48% (95% CI -47.98, -30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects. The objective was to evaluate the effects of 6 months of supplementation with Altilix ® , containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix ® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix ® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (−2.40% (95% CI −3.79, −1.01); p < 0.001), waist circumference (−2.76% (95% CI −4.55, −0.96); p = 0.003), HbA1c (−0.95% (95% CI −1.22, −0.67); p < 0.001), plasma lipids, FLI (−21.83% (95% CI −27.39, −16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (−39.48% (95% CI −47.98, −30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix ® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix ® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects. |
| Author | Chianetta, Roberta Toth, Peter P. Magán-Fernández, Antonio Amato, Antonella Banach, Maciej Castellino, Giuseppa Patti, Angelo M. Montalto, Giuseppe Cicero, Arrigo F. G. Nikolic, Dragana Malfa, Giuseppe Antonio Rizzo, Manfredi |
| AuthorAffiliation | 3 Department of Drug Science, Biochemistry Section, University of Catania, 95125 Catania, Italy 1 Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, 90100 Palermo, Italy; castellinogiusy@gmail.com (G.C.); draggana.nikolic@gmail.com (D.N.); amaganf@ugr.es (A.M.-F.); chianetta.roberta8@gmail.com (R.C.); angelomaria.patti@unipa.it (A.M.P.); giuseppe.montalto@unipa.it (G.M.); manfredi.rizzo@unipa.it (M.R.) 4 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90100 Palermo, Italy; antonella.amato@unipa.it 5 Department of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA; peter.toth@srfc.com 6 Department of Preventive Cardiology, CGH Medical Center, Sterling, IL 61081, USA 8 Department of Medical and Surgical Sciences, University of Bologna, 40 |
| AuthorAffiliation_xml | – name: 3 Department of Drug Science, Biochemistry Section, University of Catania, 95125 Catania, Italy – name: 4 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90100 Palermo, Italy; antonella.amato@unipa.it – name: 2 Periodontology Department, School of Dentistry, University of Granada, 18071 Granada, Spain – name: 1 Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, 90100 Palermo, Italy; castellinogiusy@gmail.com (G.C.); draggana.nikolic@gmail.com (D.N.); amaganf@ugr.es (A.M.-F.); chianetta.roberta8@gmail.com (R.C.); angelomaria.patti@unipa.it (A.M.P.); giuseppe.montalto@unipa.it (G.M.); manfredi.rizzo@unipa.it (M.R.) – name: 5 Department of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA; peter.toth@srfc.com – name: 8 Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy; arrigo.cicero@unibo.it – name: 6 Department of Preventive Cardiology, CGH Medical Center, Sterling, IL 61081, USA – name: 7 Department of Hypertension, Medical University of Lodz, 90137 Lodz, Poland; maciejbanach77@gmail.com |
| Author_xml | – sequence: 1 givenname: Giuseppa surname: Castellino fullname: Castellino, Giuseppa – sequence: 2 givenname: Dragana surname: Nikolic fullname: Nikolic, Dragana – sequence: 3 givenname: Antonio orcidid: 0000-0001-6430-2276 surname: Magán-Fernández fullname: Magán-Fernández, Antonio – sequence: 4 givenname: Giuseppe Antonio orcidid: 0000-0002-6733-0587 surname: Malfa fullname: Malfa, Giuseppe Antonio – sequence: 5 givenname: Roberta surname: Chianetta fullname: Chianetta, Roberta – sequence: 6 givenname: Angelo M. surname: Patti fullname: Patti, Angelo M. – sequence: 7 givenname: Antonella surname: Amato fullname: Amato, Antonella – sequence: 8 givenname: Giuseppe surname: Montalto fullname: Montalto, Giuseppe – sequence: 9 givenname: Peter P. surname: Toth fullname: Toth, Peter P. – sequence: 10 givenname: Maciej orcidid: 0000-0001-6690-6874 surname: Banach fullname: Banach, Maciej – sequence: 11 givenname: Arrigo F. G. orcidid: 0000-0002-4367-3884 surname: Cicero fullname: Cicero, Arrigo F. G. – sequence: 12 givenname: Manfredi surname: Rizzo fullname: Rizzo, Manfredi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31731527$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkttu1DAQhiNURA_0hgdAlrhBFQHbcexsL5CW5dBKW1GxcG05zuyuV44dHKewPBQPwQvwSjj0QKmQmBvbmm9-_5qZ_WzHeQdZ9ojg50UxwS_cQFLQssL3sj2KBc05Z8XOrftudtj3GzyGwIIXD7LdgoiClFTsZT-nNhprvv74jhZD11lowUU08y4q44xbodna-uBX4IxGU20apFyD5kMEb41Dp20X_AU06AQ6FRMyZmcqNMa3EFWdII3OVVDpBaFHqWQx1BvQsUdfTFyjsxtqsXVNSFXHaIo4OksO1uhDkvOt-QbNM_TaD7WF_FX6Nr3OrdJQ-3x0Gry1ycIiDs32YXZ_qWwPh1fnQfbp7ZuPs5N8_v7d6Ww6zzUrJjHXgnFVl7pcTogWS6CsIZyWRFBOJ0Wla85LRYFzXNeYVWLCNBMpURNNC6LK4iB7eanbDXULjU5dC8rKLphWha30ysi_M86s5cpfSF4lmWoUeHolEPznAfooW9NrsFY58EMvKcPjx4yJ_6NplgQTLKqEPrmDbvwQXOrEb4pVJWcj9fi2-RvX12uRAHwJ6OD7PsBSahPTfMdmK2MlwXJcPvln-VLJ0Z2Sa9V_wL8AIoPcZQ |
| CitedBy_id | crossref_primary_10_1002_mnfr_202001048 crossref_primary_10_1016_j_atherosclerosis_2025_119177 crossref_primary_10_1016_j_phymed_2023_154961 crossref_primary_10_3390_metabo12111145 crossref_primary_10_3390_nu14071440 crossref_primary_10_1016_j_prmcm_2024_100401 crossref_primary_10_1111_jfbc_13358 crossref_primary_10_3390_ijms242115995 crossref_primary_10_1080_10408398_2022_2095349 crossref_primary_10_1016_j_lfs_2020_117990 crossref_primary_10_1002_ptr_8043 crossref_primary_10_1097_HCO_0000000000000874 crossref_primary_10_3390_biom15020163 crossref_primary_10_1002_ptr_8020 crossref_primary_10_3390_app11209563 crossref_primary_10_3390_ijms25105189 crossref_primary_10_3389_fnut_2024_1355732 crossref_primary_10_3390_futurepharmacol4040042 crossref_primary_10_3390_ph17101354 crossref_primary_10_1177_09603271211006171 crossref_primary_10_1177_09731296231217557 crossref_primary_10_1016_j_tifs_2021_02_043 crossref_primary_10_1002_fsn3_4682 crossref_primary_10_3390_ijms23020786 crossref_primary_10_3390_nu14061155 crossref_primary_10_3390_metabo10100392 crossref_primary_10_1016_j_advnut_2023_01_002 crossref_primary_10_1080_10408398_2025_2474177 crossref_primary_10_1016_j_phrs_2022_106599 crossref_primary_10_3390_molecules28062864 crossref_primary_10_3390_nu16070924 crossref_primary_10_1097_MD_0000000000034504 crossref_primary_10_3390_ijms22031321 crossref_primary_10_1016_j_jep_2022_116091 crossref_primary_10_1002_tox_24289 crossref_primary_10_1007_s13105_023_00991_z crossref_primary_10_1016_j_biopha_2021_111334 crossref_primary_10_1016_j_jpha_2024_101097 crossref_primary_10_1089_jmf_2022_0025 crossref_primary_10_3390_ijerph17186583 crossref_primary_10_1186_s13020_021_00469_4 crossref_primary_10_3390_metabo14060346 crossref_primary_10_1016_j_dsx_2020_07_043 crossref_primary_10_3390_app11156691 crossref_primary_10_3389_fphar_2021_752926 crossref_primary_10_1111_cpr_70012 crossref_primary_10_3390_nu15020462 crossref_primary_10_3390_nu17030453 |
| Cites_doi | 10.1007/s11130-015-0503-8 10.3389/fendo.2017.00335 10.3390/nu10091153 10.3945/jn.114.193128 10.1016/j.phymed.2003.11.002 10.1002/ptr.6073 10.1515/jbcpp-2013-0141 10.1016/j.cytogfr.2015.07.002 10.1016/j.phymed.2009.03.007 10.1186/1471-230X-6-33 10.1080/10715769800300281 10.1016/j.metabol.2016.01.012 10.1007/BF00280883 10.1161/CIRCULATIONAHA.109.192644 10.1111/j.1742-1241.2010.02378.x 10.1016/j.clnu.2017.03.017 10.5114/aoms.2017.69326 10.3390/nu9050492 10.1016/j.lfs.2004.07.018 10.1123/ijsnem.18.3.313 10.1007/s12325-017-0580-1 10.1016/j.dsx.2017.05.005 10.1007/s00125-017-4340-1 10.2174/157016111796642661 10.1111/j.1365-2559.2011.04145.x 10.1002/hep.22109 10.1530/EJE-14-0112 10.5114/aoms.2017.68717 10.1210/jc.2014-2291 10.1155/2016/4030476 10.3390/molecules21050564 10.2174/1381612811319270018 10.3109/13880209.2013.777931 10.1101/cshperspect.a028415 10.1055/s-0032-1306423 10.1016/j.phrs.2018.10.007 10.3390/nu10091276 10.1093/nutrit/nux014 10.1155/2015/647832 10.1186/s12933-016-0480-8 10.1515/hmbci-2016-0018 10.1093/eurheartj/ehw106 10.1371/journal.pone.0176867 10.1093/beheco/arh107 10.1186/s12906-017-1640-4 10.1186/1471-2261-7-11 10.7326/0003-4819-152-11-201006010-00232 10.1038/ijo.2015.151 |
| ContentType | Journal Article |
| Copyright | 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2019 by the authors. 2019 |
| Copyright_xml | – notice: 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2019 by the authors. 2019 |
| DBID | AAYXX CITATION NPM 3V. 7TS 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM |
| DOI | 10.3390/nu11112580 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Physical Education Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Physical Education Index ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database CrossRef MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: Proquest Central Journals url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 2072-6643 |
| ExternalDocumentID | PMC6893885 31731527 10_3390_nu11112580 |
| Genre | Journal Article |
| GeographicLocations | United States--US Italy |
| GeographicLocations_xml | – name: United States--US – name: Italy |
| GroupedDBID | --- 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AADQD AAFWJ AAHBH AAWTL AAYXX ABUWG ACIWK ACPRK AENEX AFKRA AFRAH AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS APEBS BENPR BPHCQ BVXVI CCPQU CITATION DIK E3Z EBD ECGQY EIHBH ESTFP EYRJQ F5P FYUFA GX1 HMCUK HYE KQ8 LK8 M1P M48 MODMG M~E OK1 P2P P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM TR2 UKHRP 3V. ATCPS BBNVY BHPHI GROUPED_DOAJ HCIFZ M0K M7P NPM 7TS 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c439t-c746ab5c5f91c7fe24d162517262938cb665a2e660bb048794c47938b1c231a53 |
| IEDL.DBID | M48 |
| ISSN | 2072-6643 |
| IngestDate | Thu Aug 21 14:05:01 EDT 2025 Fri Jul 11 00:10:17 EDT 2025 Mon Jul 21 11:26:27 EDT 2025 Sat Aug 23 13:36:37 EDT 2025 Thu Jan 02 23:00:14 EST 2025 Tue Jul 01 02:30:42 EDT 2025 Thu Apr 24 23:06:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | metabolic syndrome non-alcoholic fatty liver disease type 2 cynara dietary supplements diabetes mellitus cardiovascular diseases |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c439t-c746ab5c5f91c7fe24d162517262938cb665a2e660bb048794c47938b1c231a53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 These authors contributed equally to the work. |
| ORCID | 0000-0001-6430-2276 0000-0001-6690-6874 0000-0002-6733-0587 0000-0002-4367-3884 |
| OpenAccessLink | https://www.proquest.com/docview/2315485648?pq-origsite=%requestingapplication% |
| PMID | 31731527 |
| PQID | 2315485648 |
| PQPubID | 2032353 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6893885 proquest_miscellaneous_2400487447 proquest_miscellaneous_2315101078 proquest_journals_2315485648 pubmed_primary_31731527 crossref_citationtrail_10_3390_nu11112580 crossref_primary_10_3390_nu11112580 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20191025 |
| PublicationDateYYYYMMDD | 2019-10-25 |
| PublicationDate_xml | – month: 10 year: 2019 text: 20191025 day: 25 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Nutrients |
| PublicationTitleAlternate | Nutrients |
| PublicationYear | 2019 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Rizzo (ref_47) 2015; 100 Alberti (ref_20) 2009; 120 Panahi (ref_28) 2018; 32 Chalasani (ref_54) 2012; 55 Rizzo (ref_30) 2010; 64 Brown (ref_32) 1998; 29 ref_10 Cicero (ref_40) 2017; 13 Dittrich (ref_50) 2015; 26 Heidarian (ref_45) 2013; 51 Wittemer (ref_44) 2005; 12 Gebhardt (ref_33) 1996; 10 Matthews (ref_21) 1985; 28 Basta (ref_14) 2008; 18 ref_25 Cuthbertson (ref_53) 2014; 171 Rizzo (ref_24) 2016; 15 Rezazadeh (ref_12) 2018; 37 ref_22 Schulz (ref_19) 2010; 152 Rangboo (ref_15) 2016; 2016 Englisch (ref_39) 2000; 50 He (ref_18) 2017; 8 ref_27 Mikhailidis (ref_1) 2011; 9 Rondanelli (ref_34) 2013; 80 Oboh (ref_35) 2015; 26 Albrecht (ref_23) 2013; 13 Mikhailidis (ref_2) 2017; 75 ref_36 Isokuortti (ref_37) 2017; 60 Samochowiec (ref_31) 1962; 14 Patti (ref_7) 2018; 14 Chatrath (ref_41) 2012; 32 Kim (ref_42) 2008; 47 Nakagawa (ref_26) 2004; 15 Alamri (ref_51) 2016; 26 Piepoli (ref_9) 2016; 37 Dobson (ref_5) 2016; 40 Liu (ref_16) 2014; 144 Ali (ref_52) 2017; 11 Santos (ref_38) 2018; 137 Sa (ref_17) 2015; 2015 Lupattelli (ref_29) 2004; 76 ref_43 Rizzo (ref_46) 2013; 19 (ref_49) 2018; 10 Levene (ref_3) 2012; 61 Cicero (ref_8) 2017; 34 Huber (ref_13) 2009; 16 ref_48 Affes (ref_11) 2015; 70 Fazel (ref_4) 2016; 65 ref_6 |
| References_xml | – volume: 70 start-page: 441 year: 2015 ident: ref_11 article-title: Pharmacological studies of artichoke leaf extract and their health benefits publication-title: Plant Foods Hum. Nutr. doi: 10.1007/s11130-015-0503-8 – volume: 8 start-page: 335 year: 2017 ident: ref_18 article-title: Relationship between hypothyroidism and non-alcoholic fatty liver disease: A systematic review and meta-analysis publication-title: Front. Endocrinol. doi: 10.3389/fendo.2017.00335 – ident: ref_10 doi: 10.3390/nu10091153 – volume: 144 start-page: 1009 year: 2014 ident: ref_16 article-title: Luteolin alleviates alcoholic liver disease induced by chronic and binge ethanol feeding in mice publication-title: J. Nutr. doi: 10.3945/jn.114.193128 – volume: 55 start-page: 2005 year: 2012 ident: ref_54 article-title: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american gastroenterological association, american association for the study of liver diseases, and american college of gastroenterology publication-title: Gastroenterology – volume: 12 start-page: 28 year: 2005 ident: ref_44 article-title: Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of artichoke leaf extracts in humans publication-title: Phytomedicine doi: 10.1016/j.phymed.2003.11.002 – volume: 32 start-page: 1382 year: 2018 ident: ref_28 article-title: Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial publication-title: Phytother. Res. doi: 10.1002/ptr.6073 – volume: 26 start-page: 165 year: 2015 ident: ref_35 article-title: Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): A comparative study publication-title: J. Basic Clin. Physiol. Pharmacol. doi: 10.1515/jbcpp-2013-0141 – volume: 26 start-page: 595 year: 2015 ident: ref_50 article-title: Systems biology of il-6, il-12 family cytokines publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2015.07.002 – volume: 16 start-page: 801 year: 2009 ident: ref_13 article-title: Artichoke leave extract for chronic hepatitis c—A pilot study publication-title: Phytomedicine doi: 10.1016/j.phymed.2009.03.007 – ident: ref_22 doi: 10.1186/1471-230X-6-33 – volume: 29 start-page: 247 year: 1998 ident: ref_32 article-title: Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro publication-title: Free Radic. Res. doi: 10.1080/10715769800300281 – volume: 65 start-page: 1017 year: 2016 ident: ref_4 article-title: Epidemiology and natural history of non-alcoholic fatty liver disease publication-title: Metabolism doi: 10.1016/j.metabol.2016.01.012 – volume: 28 start-page: 412 year: 1985 ident: ref_21 article-title: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man publication-title: Diabetologia doi: 10.1007/BF00280883 – volume: 120 start-page: 1640 year: 2009 ident: ref_20 article-title: Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.192644 – volume: 64 start-page: 1632 year: 2010 ident: ref_30 article-title: Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? publication-title: Int. J. Clin. Pract. doi: 10.1111/j.1742-1241.2010.02378.x – volume: 37 start-page: 790 year: 2018 ident: ref_12 article-title: Antioxidant response to artichoke leaf extract supplementation in metabolic syndrome: A double-blind placebo-controlled randomized clinical trial publication-title: Clin. Nutr. doi: 10.1016/j.clnu.2017.03.017 – volume: 13 start-page: 965 year: 2017 ident: ref_40 article-title: Lipid lowering nutraceuticals in clinical practice: Position paper from an international lipid expert panel publication-title: Arch. Med. Sci. doi: 10.5114/aoms.2017.69326 – ident: ref_43 doi: 10.3390/nu9050492 – volume: 76 start-page: 775 year: 2004 ident: ref_29 article-title: Artichoke juice improves endothelial function in hyperlipemia publication-title: Life Sci. doi: 10.1016/j.lfs.2004.07.018 – volume: 18 start-page: 313 year: 2008 ident: ref_14 article-title: The influence of supplementation with artichoke (cynara scolymus l.) extract on selected redox parameters in rowers publication-title: Int. J. Sport Nutr. Exerc. Metab. doi: 10.1123/ijsnem.18.3.313 – volume: 34 start-page: 1966 year: 2017 ident: ref_8 article-title: Short-term effects of a combined nutraceutical on lipid level, fatty liver biomarkers, hemodynamic parameters, and estimated cardiovascular disease risk: A double-blind, placebo-controlled randomized clinical trial publication-title: Adv. Ther. doi: 10.1007/s12325-017-0580-1 – volume: 11 start-page: S721 year: 2017 ident: ref_52 article-title: The association between ghrelin levels and markers of arterial stiffness and inflammatory markers in saudi subjects with metabolic syndrome publication-title: Diabetes Metab. Syndr. doi: 10.1016/j.dsx.2017.05.005 – volume: 60 start-page: 1873 year: 2017 ident: ref_37 article-title: Use of homa-ir to diagnose non-alcoholic fatty liver disease: A population-based and inter-laboratory study publication-title: Diabetologia doi: 10.1007/s00125-017-4340-1 – volume: 9 start-page: 533 year: 2011 ident: ref_1 article-title: “European panel on low density lipoprotein (ldl) subclasses”: A statement on the pathophysiology, atherogenicity and clinical significance of ldl subclasses publication-title: Curr. Vasc. Pharmacol. doi: 10.2174/157016111796642661 – volume: 61 start-page: 141 year: 2012 ident: ref_3 article-title: The epidemiology, pathogenesis and histopathology of fatty liver disease publication-title: Histopathology doi: 10.1111/j.1365-2559.2011.04145.x – volume: 50 start-page: 260 year: 2000 ident: ref_39 article-title: Efficacy of artichoke dry extract in patients with hyperlipoproteinemia publication-title: Arzneimittelforschung – volume: 47 start-page: 1363 year: 2008 ident: ref_42 article-title: Serum activity of alanine aminotransferase (alt) as an indicator of health and disease publication-title: Hepatology doi: 10.1002/hep.22109 – volume: 171 start-page: 561 year: 2014 ident: ref_53 article-title: External validation of the fatty liver index and lipid accumulation product indices, using 1h-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-14-0112 – volume: 14 start-page: 115 year: 1962 ident: ref_31 article-title: The action of herbs and roots of artichokes (cynara scolymnus) and cardoon (cynara cardunculus) on the development of experimental atherosclerosis in white rats publication-title: Diss Pharm – volume: 14 start-page: 422 year: 2018 ident: ref_7 article-title: Natural approaches in metabolic syndrome management publication-title: Arch. Med. Sci. doi: 10.5114/aoms.2017.68717 – volume: 100 start-page: 603 year: 2015 ident: ref_47 article-title: Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2014-2291 – volume: 2016 start-page: 4030476 year: 2016 ident: ref_15 article-title: The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis publication-title: Int. J. Hepatol. doi: 10.1155/2016/4030476 – ident: ref_36 doi: 10.3390/molecules21050564 – volume: 19 start-page: 4953 year: 2013 ident: ref_46 article-title: A review of the cardiovascular and anti-atherogenic effects of ghrelin publication-title: Curr. Pharm. Des. doi: 10.2174/1381612811319270018 – volume: 51 start-page: 1104 year: 2013 ident: ref_45 article-title: Protective effect of artichoke (cynara scolymus) leaf extract against lead toxicity in rat publication-title: Pharm. Biol. doi: 10.3109/13880209.2013.777931 – volume: 10 start-page: a028415 year: 2018 ident: ref_49 article-title: Interleukin-6 family cytokines publication-title: Cold Spring Harb. Perspect. Biol. doi: 10.1101/cshperspect.a028415 – volume: 10 start-page: 89 year: 1996 ident: ref_33 article-title: Inhibition of hepatic cholesterol biosynthesis by artichoke leaf extracts is mainly due to luteolin publication-title: Cell Biol. Toxicol. – volume: 13 start-page: 2976 year: 2013 ident: ref_23 article-title: Development of a novel assay for proprotein converting enzyme activity on a multiplex bead-based array system publication-title: Proteomics – volume: 32 start-page: 22 year: 2012 ident: ref_41 article-title: Dyslipidemia in patients with nonalcoholic fatty liver disease publication-title: Semin. Liver Dis. doi: 10.1055/s-0032-1306423 – volume: 137 start-page: 170 year: 2018 ident: ref_38 article-title: The effect of artichoke on lipid profile: A review of possible mechanisms of action publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2018.10.007 – ident: ref_27 doi: 10.3390/nu10091276 – volume: 75 start-page: 307 year: 2017 ident: ref_2 article-title: Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation publication-title: Nutr. Rev. doi: 10.1093/nutrit/nux014 – volume: 2015 start-page: 647832 year: 2015 ident: ref_17 article-title: Effects on liver lipid metabolism of the naturally occurring dietary flavone luteolin-7-glucoside publication-title: Evid. Based Complement. Altern. Med. doi: 10.1155/2015/647832 – volume: 15 start-page: 162 year: 2016 ident: ref_24 article-title: Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-016-0480-8 – volume: 26 start-page: 3 year: 2016 ident: ref_51 article-title: The role of ghrelin in the regulation of glucose homeostasis publication-title: Horm. Mol. Biol. Clin. Investig. doi: 10.1515/hmbci-2016-0018 – volume: 37 start-page: 2315 year: 2016 ident: ref_9 article-title: 2016 european guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the european association for cardiovascular prevention & rehabilitation (eacpr) publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehw106 – ident: ref_6 doi: 10.1371/journal.pone.0176867 – volume: 15 start-page: 1044 year: 2004 ident: ref_26 article-title: A farewell to bonferroni: The problems of low statistical power and publication bias publication-title: Behav. Ecol. doi: 10.1093/beheco/arh107 – ident: ref_48 doi: 10.1186/s12906-017-1640-4 – ident: ref_25 doi: 10.1186/1471-2261-7-11 – volume: 152 start-page: 726 year: 2010 ident: ref_19 article-title: Consort 2010 statement: Updated guidelines for reporting parallel group randomized trials publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-152-11-201006010-00232 – volume: 80 start-page: 17 year: 2013 ident: ref_34 article-title: Health-promoting properties of artichoke in preventing cardiovascular disease by its lipidic and glycemic-reducing action publication-title: Monaldi Arch. Chest Dis. – volume: 40 start-page: 153 year: 2016 ident: ref_5 article-title: Metabolically healthy and unhealthy obesity: Differential effects on myocardial function according to metabolic syndrome, rather than obesity publication-title: Int. J. Obes. doi: 10.1038/ijo.2015.151 |
| SSID | ssj0000070763 |
| Score | 2.4390688 |
| Snippet | The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its... The objective was to evaluate the effects of 6 months of supplementation with Altilix , containing chlorogenic acid and its derivatives, and luteolin and its... [...]increasing evidence indicates that specific supplements or nutraceuticals have important hepatoprotective roles, improving liver enzymes as well as liver... The objective was to evaluate the effects of 6 months of supplementation with Altilix ® , containing chlorogenic acid and its derivatives, and luteolin and its... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 2580 |
| SubjectTerms | blood lipids body weight chlorogenic acid Cytokines Diabetes Disease prevention Double-blind studies Enzymes Fatty liver Functional foods & nutraceuticals Gastroenterology Lipids Liver diseases luteolin men Metabolic syndrome nutrition risk assessment Obesity Oxidative stress placebos Plasma Substance abuse treatment transaminases ultrasonography waist circumference women Womens health |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3bbtNAEF1BeeEFQcvFbakGgZCQsJp4vbs2L5WJqCJEUQVUypvlvUS15NilcSTKR_ER_AC_1Jm147aA-hjvxFlpZmfPnp2cYeyVTRMu6c8xaqRsSBdFoU4LHkZz4wyXKU8L4iGPPsvpSfxxJmY94bbsyyrXOdEnatsY4sj3EYcguBYyTg7OvofUNYpuV_sWGnfZPZIuo6hWMzVwLF7LRvJOlZTj6X6_XlGKiASpQF7fh_4Bl3_XSF7bdA4fsgc9WoSsc-8jdsfVm2wrq_GkvLiA1-DrNz0xvsX-ZFVbVuWP37_At-r0vB-Q-lTXBAImp3g2bzBgSgOZKS0UtYVPq9ZR3x7o2AVnYeqoyNr40YmvVl24FkOlwmfHBdVykSAn4Fcw6RCLswQic-FosPraqyC8gwwkYNbA0S_4umZR_nT2LSBo15UL3-PP4qdjIvJ1E066ovkKp0DFjReP2cnhh2-Tadi3awgNopo2NCqWhRZGzNOxUXMXxXYsSREtkogpEqOlFEXkpBxpjXkDE4EhWi_RY4POLQR_wjbqpnbPGGhuRSqsleR0bgxiiigxokjkiEd6ZAL2Zu283PRa5tRSo8rxTEOOzq8cHbCXg-1Zp-DxX6vddQzk_Spe5lcxF7AXwzCuP7pUKWrXrDobTGsY5LfY-ESp4lgF7GkXVsNUEL9xai0cMHUj4AYD0v--OVKXp14HXCLWTBKxffvUd9h9BHkp7beR2GUb7fnKPUcg1eo9v1ouAQfEIiA priority: 102 providerName: ProQuest |
| Title | Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31731527 https://www.proquest.com/docview/2315485648 https://www.proquest.com/docview/2315101078 https://www.proquest.com/docview/2400487447 https://pubmed.ncbi.nlm.nih.gov/PMC6893885 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwELbG9oUvCBgv2UZlBEJCIpA6sZ0gIZRVGxWiUzWo1G9V_FItUpqwLZVWfhQ_gl_AT-LOSQMdE-Jj4kts1ee75y7Xewh5bpI4FPjnGBlI4-OHIl8lWeizubY6FEmYZJiHHJ2I4ST6OOXTLbLm72x_wMsbQzvkk5pcFK-vzlfv4cC_w4gTQvY35RLPPeMxhO474JEkMhmMWpjfwGBYiSNVY4FkvgAv3HQqvfb4pm_6C3Ber5v8wxEd3yV3WgRJ02bL75EtW94nu2kJ0fNiRV9QV9PpkuW75Gda1HmRX9Ef36nj73TJQIotqRpmCDo4g4C9Ai3KNU11bmhWGvppWVsk86FNysEaOrRYea3d6MCVsC5sDfpTwL1xhgVe2KWTwiNgiTC1c0kxw0tHndTntjXCW5pSQcGUwOgpvK5a5N-seUUByavC-ocwLVyNMbuvKn_QVNIXsASseFw9IJPjoy-Dod9yOPgaoE7taxmJTHHN50lfy7llkekLbJPGBACNWCsheMasEIFSYEzAOmjM9cWqrwF5Zjx8SLbLqrSPCVWh4Qk3BlSLR6HWADRYrHkWiyBkKtAeebnevZluG5wjz0Yxg0AHd3r2e6c98qyT_dq09bhR6mCtBLO1Zs4YTh9zEcUeedoNw6HELy1ZaatlIwO2DjT_HzLOesookh551OhVtxQAdSHyDXtEbmhcJ4BNwTdHyvzMNQcXAEDjmO_9x7z75DbAvwQ9MeMHZLu-WNonALFq1SO35FT2yM7h0cn4FK4-TPs9d6Z-Ady6K1s |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF1V5QFeEFAuhgKLuEhIWHW83rWNhJAbqFKaVBW0Ut5c7yWqJccujSMIH9WP4Af4pc6sY7cF1Lc-JjtOVpqzc9vxGUJe6ThiAl-OCb1Qu3hR5Mo4Y64_UUYxEbM4wzrkaFcMDoIvYz5eIaftuzDYVtnaRGuodaWwRr4BcQgE11wE0cfj7y5OjcLb1XaERgOLHbP4ASnb7MP2J9Dva9_f-rzfH7jLqQKuAudbuyoMRCa54pO4p8KJ8QPdE0jc5QtwfZGSQvDMN0J4UgK8Aa8Kq0-R7CnYQ4ZTIsDk3wDH62GyF47DrqZjuXMEa1hQGYu9jXKOJsnnyDp50e_9E8z-3ZN5wclt3SG3l9EpTRo43SUrprxH1pISMvPpgr6htl_UFuLXyJ-kqPMi__n7lNrRoLbOSJHtqhk6QftHRXVSAUBzRROVa5qVmg7ntcE5QbSpZhhNBwabupVd7dvu2KmpAZoFfLeXYe8YEoBSeASMHFaNZhSLx3TUSX1bsi68pwkVFKwUrH6Fn6um-S-j31FIEmRh3E34W_i0hxcHsnL7TZN-AVvAZsrFfXJwLYp8QFbLqjSPCJVM85hrLRBkTCmIYfxI8SwSHvOlpxzytlVeqpbc6TjCo0ghh0JFp-eKdsjLTva4YQz5r9R6i4F0aTVm6TnGHfKiW4bzjpc4WWmqeSMDZhQO1RUy1jCHQRA65GEDq24rEC8yHGXskPAS4DoB5Bu_vFLmR5Z3XEBsG0X88dVbf05uDvZHw3S4vbvzhNyCADNGX-_zdbJan8zNUwjiavnMnhxKDq_7qJ4BQ9Fc7w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF1VqYR4QZRyMS2wiIuEhJXE613bSAi5aaOUtlFUqNQ313uJasmxS-MIwkfxATzyA_wSM761BdS3PiY7TlaaM5edHZ8h5KUOfCbw5Riv52kbL4psGcTMdqbKKCYCFsRYhzwYi9GR-_GYH6-Qn827MNhW2fjE0lHrXGGNvAt5CCTXXLh-d1q3RUy2hx_Ovtg4QQpvWptxGhVE9szyKxzf5u93t0HXrxxnuPN5MLLrCQO2gkBc2MpzRSy54tOgr7ypcVzdF0ji5QgIg76SQvDYMUL0pASoA3YVVqJ82VewnxgnRoD7X_XwVNQhq1s748lhW-EpmXQEqzhRGQt63WyBDsrhyEF5OQr-k9r-3aF5KeQN75I7da5Kwwpca2TFZPfIepjBOX22pK9p2T1aluXXye8wLZI0-fbrBy0HhZZVR4rcV9UICjo4TfPzHOCaKBqqRNM403R_URicGkSr2obRdGSwxVuVq4OyV3ZmCgBqCt9NYuwkQzpQCo-Ay8Ma0pxiKZketFKfag6GdzSkgoLPgtVD-Ll8lnw3-i2FI4NMjb0FfwufJniNIHN7ULXsp7AFbK1c3idHN6LKB6ST5Zl5RKhkmgdca4GQY0pBRuP4ise-6DFH9pRF3jTKi1TNpI4DPdIITlSo6OhC0RZ50cqeVfwh_5XabDAQ1T5kHl0g3iLP22WwfrzSiTOTLyoZcKpgYtfIlG7ac13PIg8rWLVbgeyR4WBji3hXANcKIPv41ZUsOS1ZyAVkur7PH1-_9WfkFphptL873tsgtyHbDDDwO3yTdIrzhXkCGV0hn9amQ8nJTVvrHz8kYoo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Altilix+%C2%AE+Supplement+Containing+Chlorogenic+Acid+and+Luteolin+Improved+Hepatic+and+Cardiometabolic+Parameters+in+Subjects+with+Metabolic+Syndrome%3A+A+6+Month+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Study&rft.jtitle=Nutrients&rft.au=Castellino%2C+Giuseppa&rft.au=Nikolic%2C+Dragana&rft.au=Mag%C3%A1n-Fern%C3%A1ndez%2C+Antonio&rft.au=Malfa%2C+Giuseppe+Antonio&rft.date=2019-10-25&rft.issn=2072-6643&rft.eissn=2072-6643&rft.volume=11&rft.issue=11&rft_id=info:doi/10.3390%2Fnu11112580&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6643&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6643&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6643&client=summon |